Regenerative Medicine by Haroutunian, Armen et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Armen Haroutunian, Tennison Malcolm and Thomas Zouki
Abstract
Chronic pain is a debilitating condition that affects millions of people world-wide, 
leading to physical incapacitation and financial strain. Common methods for treat-
ment include physical therapy, oral medications, injections, surgery, and neuromodu-
lation. Injectates with steroids and local anesthetics can be a temporizing measure 
with intolerable side effects. The use of autologous biologic injectates (e.g., platelet rich 
plasma, bone marrow aspirate concentrate, tissue grafts, and stem cells) is growing 
in therapeutic potential and enthusiasm, giving hope to a subset of patients that have 
either failed conventional therapy or are not candidates for traditional steroid injec-
tions. In this chapter, we will describe different cases in which regenerative medicine 
can help in painful conditions as well as neuro-degenerative conditions. Regenerative 
medicine can be the new frontier in providing long lasting relief through changes in 
cell-signaling cascades, however further trials are needed to validate their use.
Keywords: platelet rich plasma (PRP), stem cell therapy,  
bone marrow aspirate concentrate (BMAC), adipose tissue grafts, exosomes, 
mesenchymal stem cells, hematopoetic stem cells (HCC’s), pain management, 
regenerative medicine
1. Introduction
Chronic pain is a public health issue, affecting nearly a quarter of our popula-
tion, and takes different forms such as neuropathic, cancer-related or inflammatory 
pain [1]. This condition limits patients in their daily activities leading to despair and 
significant loss in quality of life. The most common methods of treatment include 
physical therapy, oral medications, injections, surgery and neuromodulation. The 
injectates that are the most commonly used include local anesthetics and steroids. 
The use of autologous biologic injectates (e.g., platelet rich plasma, bone marrow 
aspirate concentrate, tissue grafts, and stem cells) is growing in therapeutic potential 
and enthusiasm, giving hope to a subset of patients that have either failed conven-
tional therapy or are not candidates for traditional steroid injections. Continued clin-
ical trials are needed to further validate their use and help expand their application 
in the field of medicine. The theory of using these therapies for painful conditions 
stems from their cytoprotective properties, as well as their regenerative potential.
2. Terminology, history, and background
The most common types of regenerative medicine therapies include platelet rich 
plasma (PRP), stem cell therapy from bone marrow aspirate concentrate (BMAC) and 
adipose tissue grafts, and exosomes. Regenerative therapies are growing worldwide 
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(Figure 1). They are increasing from 164% in 1 year with a total of 4.1 billion dollars 
in total global funding [2]. These therapies can be used in conjunction or individu-
ally, and there is no set algorithm or protocol that dictates superiority [3]. Stem cell 
therapy in this article will refer to adult stem cells, which are multipotent and have no 
ethical concerns related to their use, as opposed to embryonic stem cells [4]. Typically, 
candidates include patients with chronic peripheral joint pain that have not responded 
to steroid injections, or cannot tolerate the medication due to side effects, including 
but not limited to hyperglycemia, hypertension, ineffective wound healing, or adrenal 
gland suppression. Although there is no set protocol, some studies recommend imple-
menting a series of three injections for PRP [5]. However, some physicians may grade 
progress and response to the initial injection as a rationale for a repeat injection.
2.1 Platelet rich plasma
PRP is the most common and readily available treatment option. It is the plasma 
fraction of blood with a high platelet concentration, as well as clotting factors, 
growth factors, chemokines, cytokines, and other plasma proteins [6]. This therapy 
helps promote stem cell migration as well as healing [7]. Commonly injected into 
joints and tendons for repair, PRP was first coined in the 1970’s and used to describe 
the platelet count in peripheral blood, used to transfuse patients with thrombo-
cytopenia [6]. PRP is obtained from blood after centrifuge, which helps separate 
components based on density gradients (Figure 2). Devices used to simplify the 
preparation of PRP are said to amplify the concentration of PRP 2–5 times the 
baseline [7]. Despite the limited clinical evidence that exists, PRP has been used to 
initiate healing for a variety of cases, most commonly including osteoarthritis (OA), 
lateral epicondylitis, rotator cuff tears, ligament and tendon injuries [7]. Recent 
randomized control trials actually demonstrate benefit in tendinopathy [7]. It has 
also been suggested that PRP can play a role in elimination neuropathic pain, thought 
to be secondary to a cascade of inflammation followed by repair via axon and tissue 
regeneration [8]. PRP has also been used as an intervertebral disc injection for low 
Figure 1. 
An atlas of regenerative medicine therapies worldwide. Adapted from alliance for regenerative medicine.
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back pain with promising clinical results, however more randomized controlled tri-
als are needed [3]. Success of this therapy will ultimately depend on the preparation 
and composition of the injectate, location, and type and extent of injury.
2.2 Adipose tissue grafts
Stem cell therapy uses non-embryonic adult stem cells described as multipotent 
stem cells, and in the clinical setting refers to therapy with mesenchymal (often 
from adipose tissue) and hematopoietic stem cells (often from bone marrow aspi-
rate) [3]. These cells are present in a variety of tissues (adipocytes, chondrocytes, 
myocytes) and are thought to play a role in immune modulation [3]. The most 
common source of mesenchymal stem cells (MSC) are found in adipose tissue, first 
discovered in 1964 by Rodell [2]. There are approximately 500 to 2500× times more 
MSC’s when compared to bone marrow [3]. Adipose derived stem cells (ASC’s) are 
the most promising stem cells identified in humans, since adipose tissue is easily 
obtained in large quantities with small donor site discomfort [4]. Sites of harvest 
include the abdomen, upper arm, thigh, and trochanteric fat deposits. Common 
mechanisms to obtain fat include liposuction or lipectomy, followed by homogeni-
zation and enzymatic digestions. Traditional cosmetic liposuction can remove large 
volume (>4 kg) or small volume (<4 kg) adipose tissue, however for purposes of 
adipose tissue grafting only 100–200 mL may be needed [9]. The resultant mate-
rial is then centrifuged. Each gram of adipose tissue yields 5 × 10^3 stem cells, 
significantly greater than bone marrow [4]. It is important to note that stem cell 
harvesting is more invasive that a simple blood draw for PRP, and could thus lead to 
an increase risk for infection or complication for patients undergoing MSC harvest-
ing [10]. If performed under local or tumescent anesthesia, there is minimal to no 
recovery time. To date, hundreds of trials are listed on the United States National 
Institutes of Health website (NIH) for the use of ASC’s. Examples of applications 
include soft tissue regeneration, skeletal tissue repair, myocardial infarction, 
immune disorders such as lupus, multiple sclerosis, Crohn’s disease, diabetes.
2.3 Bone marrow aspirate concentrate
Bone marrow aspiration is a procedure in which bone marrow is collected, usu-
ally from the pelvic iliac crest [11]. The procedure is very similar to PRP, in which the 
Figure 2. 
Blood components after centrifugation.
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product is centrifuged. The final product is called bone marrow aspirate concentrate, 
or BMAC, which contains mostly hematopoetic stem cells (HCC’s), and a much 
smaller concentration of MSCs [3]. Like MSC’s, HSC’s also contain growth factors and 
immunomodulating enzymes [11]. Unlike adipose aspiration, the concentration of 
MSC’s in bone marrow dramatically decreases with age. Like ASCs, BMAC is also  
used to treat various conditions affecting tendons, ligaments, and musculoskeletal 
injuries. Approximately 60 mL of aspirate can produce 10 mL of BMAC after centri-
fuge [11]. Again, efficacy is determined by location of injection as well as extent of tis-
sue injury. Sites include shoulders, knees, hips, various tendons, and sometimes spinal 
facet joints. Current literature demonstrates benefit in utilizing BMAC as an adjunct in 
cartilage healing, faster time to bony union, and lower rates of tendon re-rupture [11].
2.4 Exosomes
Exosomes are endocytic vesicles released by various cells including T-cells, 
B-cells, reticulocytes, mast cells, platelets, tumor cells as well as MSCs [12]. They 
are membrane-enclosed particles surrounded by a phospholipid layer and are 
enriched with micro-RNAs (miRNAs) which are believed to regulate gene expres-
sion in a post-transcriptional matter and, by that matter, play a role in tissue repair 
and regeneration [13, 14]. They are defined as nanosized membrane vesicles with a 
diameter of 30–100 nm that originate from multivesicular bodies (MVB’s) and are 
released by cells into extracellular environment (Figure 3) [12]. They are cholesterol-
rich phospholipid vesicles. There are multiple contents that are found in exosomes 
including cytokines, proteins, lipids, mRNAs, miRNAs and ribosomal RNAs [15, 16]. 
Current recommendations for extraction of exosomes suggest ultracentrifugation 
at high speeds which removes cells and microvesicles. It is time consuming, labor 
intensive, and has therefore lead to commercially available kits, such as Exoquick 
©, Invitrogen ©, and Exo-Spin ©, which reliably reduce operating time to 2 hours. 
Exosomes ultimately have the capacity to execute specific targeted therapy due to 
their ability to envelope a wide range of specific contents, including lipids, RNA’s, 
and specific protein-signaling molecules [17]. This makes them a promising tool in 
nanomedicine; however, like PRP and MSC’s, classification and purification needs to 
be standardized to ensure appropriate randomized and multicenter studies.
2.5 Mechanism of action and biology
The mechanism by which these injections treat pain is still unknown and remains 
mainly theoretical [15]. Platelets, also called thrombocytes, contain several secretory 
Figure 3. 
Multivesicular bodies (MVB’s) releasing exosomes.
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granules crucial to platelet function. Platelets are primarily responsible for aggrega-
tion and contribute to hemostasis through adhesion, activation, and aggregation. 
In recent years, research has demonstrated that platelets not only have a function in 
hemostasis, but also carry an abundance of growth factors and cytokines that affect 
inflammation, stem cell migration, and proliferation [8]. Upon activation of plate-
lets in PRP, important growth factors, namely endothelial growth factor, fibroblast 
growth factor, platelet derived growth factor, epidermal growth factor, hepatocyte 
growth factor, matrix metalloproteinases, and interleukin 8 are released and modify 
the local tissue through a complex cell signaling cascade (Figure 4) [6].
There is increasing surfacing evidence suggesting that MSC’s secrete func-
tional paracrine factors which promote tissue regeneration, protection and repair 
[18–21]. Recent studies revealed that factors are released through particles known 
as exosomes. There is now strong belief that these exosomes secreted by MSCs are 
responsible for the tissue regeneration and repair rather that the ability of MSCs to 
trans-differentiate. They are suggested as central mediators of intercellular com-
munication by transferring proteins, mRNAs and miRNAs to adjacent cells leading 
to coordinative function in organisms. Those, depending on the medium in which 
they are collected can halt breast cancer metastasis, regulate angiogenesis, remodel 
neurites and promote neurogenesis [22, 23].
Exosomes aggressively participate in the inhibition of the inflammation process. 
This known property of exosomes is now being considered as a novel therapeutic 
approach to many disease processes affecting different organ systems. Indeed, the 
benefits of the anti-inflammatory properties of exosomes has not only been dem-
onstrated in various painful conditions, but also in cardiovascular and pulmonary 
diseases as well. MSCs-secreting exosomes lead to a reduction of white blood cell 
count and reduced inflammation in hearts after ischemia-reperfusion injury, which 
in turn decrease infarct size and enhance cardiac function. Protective properties 
have also been shown in the lungs for relieving symptoms of pulmonary hyperten-
sion [24, 25]. MSCs are adult multipotent cells with the ability to self-renew and 





adipocytes [26]. MSCs were originally isolated from bone marrow, they have been 
isolated from other adult tissues such as adipose tissue, dental pulp, placenta, 
amniotic fluid, umbilical cord blood and Wharton’s jelly, and even in the brain [27]. 
The MSCs differentiation potential for tissue repair has been studied extensively 
but the pattern of MSC mediated regeneration is now shifting toward secretome-
based paracrine activity. The matter by which miRNAs play an essential role in 
physiological and pathological conditions is by regulating gene expression at the 
post-transcription level [28]. The pre-miRNA goes through an extensive biologi-
cal process prior to maturation but an exosome can contain miRNA of different 
maturation stages and their release is a controlled process dependent on the source 
and developmental stage of derived cells rather than a random process [12]. It has 
been suggested that exosomes released by MSCs contain miRNA that control the 
microenvironment in the resident niches through a balance between proliferation 
and differentiation [29]. Additionally, tissue-specific responses have been described 
for exosomes isolated from different sources. For example, adipose tissue-derived 
exosomes seem to be more effective in halting the central nervous system degen-
eration caused by Alzheimer’s disease when compared to bone marrow derived 
MSCs-derived exosomes [30]. But neurite outgrowth seems to be more responsive 
to exosomes released by menstrual fluid derived MSCs when compared to umbili-
cal cord, chorion and bone marrow. Evidence of neurite outgrowth has also been 
shown in a middle cerebral artery occlusion model. MSCs exposed to ischemic 
cerebral extracts secreted exosomes containing mi-RNA that were transferred 
to neurons and astrocytes via exosomes and promoted neurite outgrowth and 
functional recovery. The same authors reported the use of cell free MSC-generated 
exosomes administered intravenously in a subject that had suffered a stroke lead to 
improved neurite remodeling, neurogenesis and angiogenesis which in turn signifi-
cantly improved the functional recovery of the subject [31]. A similar experiment in 
which intravenous administration of MSCs-generated exosomes enhanced angio-
genesis and neurogenesis reduced the inflammation, improved spatial learning and 
sensory/motor function in a traumatic brain injury model [32].
2.6 Clinical applications
At present, the use of autologous biologic injectates in the treatment of most acute 
and chronic conditions resulting in pain is considered investigational. There are cur-
rently 977 regenerative medicine trials worldwide, including gene therapy, cell therapy, 
and tissue engineering [2]. Of those, there at 51 and 66 clinical trials in the categories 
of musculoskeletal system and central nervous system, respectively. While a myriad of 
sources has reported positive results following the use of autologous biologic injectate, 
these reports are, overall, too heterogenous and underpowered to change the clini-
cal practice of most. The absence of well-powered, level-1 data is demonstrating the 
efficacy of autologous biologic injectates may simply reflect the infancy of this field. 
Conditions recently studied for the use of autologous blood injectates include Complex 
Regional Pain syndrome (formerly called Reflex Sympathetic Dystrophy or RSD), 
OA, joint arthropathy including facet arthropathy and sacroiliitis, tendinopathies, 
degenerative disc disease, Multiple Sclerosis, headaches, migraines, and peripheral 
neuropathy. In this chapter we will discuss autologous biologic injectates in the treat-
ment of OA, spondylosis, and tendon and ligament injury.
2.7 Osteoarthritis
Osteoarthritis (OA) is the most common joint disorder in the United States, 
and is estimated to 25% of people over 18-years old [33, 34]. OA is a progressive 
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disease affecting the joints and is characterized by perturbed immune responses 
to cellular injury resulting in cartilage degeneration, synovitis, bony remodeling, 
and chronic pain. Current treatment includes NSAIDs, opiate medications, topical 
analgesics, physical therapy, lifestyle modification, intraarticular steroid injections, 
intra-articular hyaluronic acid (HA) injection, and surgery. Non-steroidal anti-
inflammatory drugs (NSAIDs), opiates, and intra-articular steroid injections are 
primarily limited negative side-effects that accompany escalations in medication 
dose and frequency. Exogenous HA has been used as a treatment modality given 
observed decreases in endogenous HA exhibited in OA joints. However, due to a 
lack of consistent evidence, HA is not recommended by the American Academy of 
Orthopedic Surgeons in treatment of patients with symptomatic OA of the knee 
[35]. At present, the therapeutic value of PRP in treating OA is a topic of debate 
and investigation. Available studies suggest its clinical benefit compared with HA 
in treating OA of the knee [36–40]. Several authors have reported meta-analyses 
demonstrating improved pain and function following intra-articular injection 
of PRP in the knee versus HA [36–38]. In a meta-analysis of 26 randomized con-
trolled trials involving 2430 patients, Tan et al. found better Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) total scores, WOMAC 
physical function, and Visual Acuity (VAS) Scores at 3, 6, and 12 months following 
PRP injection compared to HA [38]. Evidence supporting the use of PRP in hip 
OA is still lacking [39]. There is still much work to be done in understanding the 
therapeutic role of PRP in treating OA. It is an infrequently used treatment modal-
ity, a likely reflection of limited reimbursement. Presently, the Centers for Medicare 
and Medicaid Services (CMS) only cover PRP use when used for the treatment of 
chronic non-healing diabetic, pressure, or venous wounds in patients enrolled in 
clinical studies [41]. Despite growing public interest, available evidence does not 
support use of autologous stem cells in treatment of OA [42, 43]. In a meta-analysis 
of nine studies, evaluating 339 patients Huang et al. found most outcome measures 
similar between stem cell recipients and controls [43]. VAS was found to be statisti-
cally improved among stem cell patients; but, it is unclear whether the modest 
differences described were clinically relevant [43].
A new 5 year study published in 2019 demonstrates better outcomes and lower 
pain scores in patients who underwent knee arthroscopy for osteochondral knee 
injuries with and without preoperative intra-articular PRP injections. This research 
was the first study which used clinical data more than 5 years and demonstrates 
that cell therapy can promote the regeneration of articular cartilage in a lasting 
way [44].
2.8 Spondylosis
Cervical and lumbar spondylosis represent the constellation of degenerative 
changes found in the cervical and lumbar spine that progressively occur in most 
people with aging. 25% of people under 40 years of age, 50% of people over 
40 years of age, and 85% of people over 60 years of age are estimated to have cervi-
cal spondylosis [45]. Pathologically, the same degenerative processes that character-
ize OA extend to the vertebral joints and result in spondylosis often characterized 
by disc degeneration, uncinate spurring and facet arthrosis, ligamentous thickening 
and infolding, and deformity. Radiculopathy, myelopathy, discogenic pain, facet 
pain are the clinical manifestations of vertebral joint degeneration. Regenerative 
techniques for the treatment of cervical and lumbar spondylosis has been previ-
ously investigated with promising results. Further studies are needed to weigh 
safety profiles against efficacy. In an RCT of PRP vs. contrast for discogenic pain, 
Tuakli-Wosornu et al., reported significant improvements in pain and function at 
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8-week follow-up [46]. Pettine et al. reported significant reductions in pain follow-
ing BMAC use for patients with discogenic pain [47]. The principle caveat of these 
results is the scarcity of similar results demonstrated in the literature [48].
2.9 Tendon and ligament healing
Tendon and ligament injuries are a very common cause of pain and disability, 
among both the very active and the elderly. Lateral epicondylitis is significantly 
more common among working-age patients with physical workloads [49]. As much 
as 80% of patients over 80 years of age are estimated to have a rotator cuff tear 
[50]. The use of PRP for tendon and ligament healing has mixed reviews but is 
considered by many a viable treatment modality given low risks of severe associated 
complications and numerous positive results promulgated throughout the litera-
ture. In a meta-analysis of 21 studies comparing PRP to control (betamethasone 
with lignocaine, saline, corticosteroid, bupivacaine, and whole blood), Chen et al. 
found PRP significantly associated with short-term (2–6.5 months) improvements 
in VAS scores among patients with rotator cuff injuries (p < 0.01) and lateral epi-
condylitis (p < 0.01) and long-term pain control among patients with rotator cuff 
injuries (p = 0.02), lateral epicondylitis (p = 0.01), and tendinopathy (p < 0.01) 
[40]. Evidence describing the clinical utility of MSCs and BMACs a in tendon and 
ligament injuries is lacking and mostly limited to in vitro and in vivo studies [51, 52].
2.10 Future therapy
Many experimental trials continue to assess the role of these injectates in tissue 
repair of the central nervous system (CNS), cardiovascular system, hepatic, renal 
as well as musculoskeletal system [2]. Some studies demonstrate exosomal induced 
neural cell growth while others have explored with success the use of exosomes as 
a promising potential treatment option for Alzheimer’s disease and other neurode-
generative pathologies. Others demonstrate the ability of exosomes to differentiate 
into bone tissue and promote skeletal regeneration [53].
Additionally, regenerative therapies such as PRP have shown a lot of promise 
in dermatology including prevention of hair loss, the treatment of scars and post 
procedure recovery, skin rejuvenation, dermal augmentation, and the treatment of 
striae distensae [54, 55]. Despite the lack of insurance coverage, these therapeutic 
modalities show much promise in the innovative world of medicine and esthetics.
3. Conclusion
These various injectates present a novel and promising treatment for many 
degenerative conditions including neurological and musculoskeletal diseases. Not 
only can biologics relieve symptoms in painful conditions, but also they can halt the 
degeneration of tissues, regenerate tissue and prolong their lifespan. PRP, MSC’s, 
and exosomes have made considerable progress and will therefore undoubtedly 
offer new and exciting prospects for a variety of musculoskeletal and nervous 
system conditions. Their utility in conditions such as osteoarthritis, spondylosis, 
and tendon and ligamentous injuries are gaining popularity with emerging clinical 
reports of their efficacy.
The thought that tissue repair and regeneration was a function of the MSCs 
themselves is now shifting toward the thinking that, exosomes, secreted by MSCs 
have a more direct role in the process. These exosomes can have a different effect 
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They exert their function by communicating in a paracrine fashion with the sur-
rounding tissue and initiate a process of cellular differentiation and proliferation, 
playing an important role in tissue repair. The use of exosomes shows promising 
results in disease processes that have no current available treatment. The use of 
biologic injectates for painful conditions deserves further consideration. Large, 
well-constructed studies are needed to better understand their applications and 
extents of their roles in degenerative conditions.
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